Patient Five Cancer-Free After Single PDT Treatment

Theralase Provides Update on 9 Months Post Treatment Cystoscopy Analysis

TORONTO, ONTARIO / ACCESSWIRE / November 8, 2018 / Theralase Technologies Inc. ("Theralase®" or the "Company")TLT TLTFF, a clinical stagepharmaceutical company dedicated to the research and development of lightactivated Photo Dynamic Compounds ("PDCs") and their associated drugformulations intended to safely andeffectively destroy various cancers has provided anupdate on patient five, enrolled and treated in the recently completed Phase IbNon-Muscle Invasive Bladder Cancer ("NMIBC")clinical study ("Study").

The Study's purpose was to evaluate TLD-1433,Theralase's lead PDC, for the primary endpoint of safety and tolerability, witha secondary endpoint of pharmacokinetics (movement and exit of drug withintissue) and an exploratory endpoint of efficacy.

Theralase'sAnti-Cancer Treatment involves the instillation of a water-based solution of Theralase'slead anti-cancer PDC, TLD-1433 at the Therapeutic Dose (0.70 mg/cm2), via a catheterinserted through the urethra into the bladder of the patient, to allow the PDCto be preferentially absorbed by NMIBC tumours. The bladder is then drained ofthe solution, flushed with sterile water to remove non-absorbed solution andrefilled with sterile water via a cystoscope. A fibre optic assembly, known asa Laser Emitter emits laser light toactivate TLD-1433, while a proprietary Dosimetry System detects the emitted laserlight, used for patient safety and efficacy. Both devices are inserted through thecystoscope, with the sole purpose of activating the absorbed PDC to destroy theNMIBC tumours.

Thetreatment was well tolerated by the patient, who demonstrated no tumour recurrenceor presence of disease at the 90 day or 180 day clinical and cystoscopy assessment.

Thepatient has met Study endpoints demonstratingachievement of the primary, secondary and exploratory endpoints at 90 and 180days and now at 270 days post treatment that marks a new achievement for theCompany.

Arkady Mandel, M.D., Ph.D., D. Sc., Interim Chief Executive Officer andChief Scientific Officer of Theralase stated, "This is an example of the enormous opportunity that awaits thisyoung Company in the treatment of cancer. For NMIBC, a Complete Response ("CR") is defined by the FDA as the definitiveendpoint for single-arm intravesical studies of patients who present with BCG-UnresponsiveCarcinoma In-Situ ("CIS") disease,with or without resected papillary tumours. In the proposed Phase II NMIBCclinical study, the Company is providing two treatment procedures (therapeutic atDay 0 and maintenance at Day 180). The latest data on patient five is extremelyencouraging, in that it demonstrates after only one treatment procedure, CR at3, 6 and now 9 months post-treatment has been obtained. If the efficacy resultsare able to be demonstrated at 12 months post-treatment, in a larger patientpopulation, conducted in a well-designed Phase II NMIBC clinical study, thenthe Theralase Anti-Cancer Technology has the potential to be the next goldstandard in the treatment of NMIBC. The Theralase Anti-Cancer Technology isalso multi-faceted, in that the technology is able to be adapted to the treatmentof additional cancer indications, if successfully validated in independent clinicalstudies. Pending successful commencement of the Phase II NMIBC clinical study, theCompany plans to investigate the commencement of an additional Phase Ibclinical study for a new cancer indication."

About the PhaseII NMIBC Clinical Study:

"A Phase II Clinical Study of Intravesical Photo Dynamic Therapy inPatients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer or PatientsWho are Intolerant to BCG Therapy" will utilize the Therapeutic Dose(0.70 mg/cm2) of TLD-1433 and will focus on the treatment ofapproximately 100 NMIBC patients in approximately 20 clinical sites located inCanada, the US and internationally, with a primary endpoint of efficacy.

The endpointsof the Phase II NMIBC Clinical Study will be:

Primary(Efficacy) - Evaluated by Complete Response ("CR")in patients with Carcinoma In-Situ ("CIS") with or without resectedpapillary disease at 90 days post-treatment with duration of CR evaluated at360 days post-treatment.

PatientCR is defined as at least one of the following:

1)Negative cystoscopy and negative (including atypical) urine cytology
2)Positive cystoscopy with biopsy-proven benign or low-grade NMIBC
3)Negative cystoscopy with malignant urine cytology, if cancer is found in theupper tract or prostatic urethra and random bladder biopsies are negative

Secondary (Safety) - Evaluatedby the incidence and severity of Adverse Events ("AEs") Grade 4 orhigher that do not resolve within 360 days post-treatment; whereby:

Grade 1= Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening ordisabling and Grade 5 = Death

ProposedPhase II Clinical Study Treatment Plan:

About TheralaseTechnologies Inc.

Theralase® is a clinicalstage pharmaceutical company dedicated to the research and development of lightactivated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.

Additional information isavailable at www.theralase.comand www.sedar.com.

This news release contains "forward-lookingstatements" which reflect the current expectations of management of theCorporation's future growth, results of operations, performance and businessprospects and opportunities. Such statements include, but are not limited to,statements regarding Theralase's proposed development plans with respect toPhoto Dynamic Compounds and their drug formulations. Wherever possible, wordssuch as "may", "would", "could","should", "will", "anticipate", "believe","plan", "expect", "intend","estimate", "potential for" and similarexpressions have been used to identify these forward-looking statements. Thesestatements reflect management's current beliefs with respect to future eventsand are based on information currently available to management. Forward-lookingstatements involve significant risks, uncertainties and assumptions includingwith respect to the ability of Theralase to: successfully fund and complete aPhase II NMIBC clinical study, secure the requisite regulatory approvals tocommence and fund a Phase IINMIBC clinical study and implement itsdevelopment plans. Many factors could cause the Corporation's actual results,performance or achievements to be materially different from any future results,performance or achievements that may be expressed or implied by suchforward-looking statements; including, without limitation, those listed in thefilings made by the Corporation with the Canadian securities regulatory authorities(which may be viewed at www.sedar.com). Should one or more of these risks oruncertainties materialize or should assumptions underlying the forward lookingstatements prove incorrect, actual results, performance or achievements mayvary materially from those expressed or implied by the forward-lookingstatements contained in this news release. These factors should be consideredcarefully and prospective investors should not place undue reliance on theforward-looking statements. Although the forward-looking statements containedin the press release are based upon what management currently believes to bereasonable assumptions, the Corporation cannot assure prospective investorsthat actual results, performance or achievements will be consistent with theseforward-looking statements. The Corporation disclaims any intention orobligation to revise forward-looking statements whether as a result of newinformation, future developments or otherwise except as required by law. Allforward-looking statements are expressly qualified in their entirety by thiscautionary statement.

Neither TSX Venture Exchange nor itsRegulation Services Provider (as that term is defined in the policies of theTSX Venture Exchanges) accepts responsibility for the adequacy or accuracy ofthis release.

For More Information:

1.866.THE.LASE (843-5273)
416.699.LASE (5273)
info@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.